Dr. Burkhoff will summarize the robust body of pilot study clinical evidence demonstrating sustained and reproducible systolic blood pressure reductions associated with delivery of AVIM Therapy, along ...

The FDA has granted Breakthrough Device Designation to Orchestra BioMed's Atrioventricular Interval Modulation (AVIM) therapy, aimed at treating patients with uncontrolled hypertension who are at ...

Orchestra BioMed’s hypertension treatment is the latest medical device to earn the FDA’s breakthrough designation. The device is an atrio-ventricular interval modulation therapy, meaning it uses a ...

Orchestra BioMed (OBIO) announced a late-breaking oral presentation of data on the benefits of atrioventricular interval modulation therapy on patients with diastolic dysfunction at the Technology and ...

Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...

Atrioventricular interval modulation (AVIM) therapy for hypertension may help address this common comorbidity among patients with pacemakers. For patients with pacemakers, hypertension is a common ...

NEW HOPE, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to ...

Joint presentation by Orchestra BioMed (OBIO) and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...